Early mepolizumab initiation during remission induction is associated with lower organ damage burden in EGPA: a multicentre cohort study

Clicks: 16
ID: 329335
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #225 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: To evaluate whether early mepolizumab initiation during remission induction is associated with favourable clinical outcomes and lower organ damage burden in patients with eosinophilic granulomatosis with polyangiitis (EGPA). METHODS: This retrospective multicentre cohort study used data from Kyushu Vasculitis Cohort Study. Patients with EGPA were classified into an early mepolizumab group, in which mepolizumab was initiated within 3 months of remission induction, and a conventional group. The primary endpoint was clinical remission at 1 year, defined as Birmingham Vasculitis Activity Score (BVAS)=0 with prednisolone ≤4 mg/day. Secondary endpoints included remission at 6 months and 2 years, glucocorticoid exposure, relapse, mortality and organ damage assessed by the Vasculitis Damage Index (VDI). Longitudinal VDI values from 6 months to 2 years were analysed using linear mixed-effects model. RESULTS: Sixty-four patients were included (early mepolizumab, n = 16; conventional, n = 48). Clinical remission at 1 year was achieved more frequently in the early mepolizumab group than in the conventional group (69% vs 27%; P = 0.006). At 2 years, remission was achieved in 10/10 (100%) versus 13/45 (29%) evaluable patients (P < 0.001), and glucocorticoid discontinuation in 4/10 (40%) versus 4/45 (9%) (P = 0.029). BVAS decreased markedly in both groups. Early mepolizumab initiation was associated with lower longitudinal VDI values (β = -0.36, 95% CI - 0.70 to - 0.03; P = 0.032). CONCLUSION: Early mepolizumab initiation was associated with higher remission rates, lower glucocorticoid exposure and lower organ damage burden during the first 2 years in EGPA.
Reference Key
openalex_W7213889670 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Akihito Maruyama, Nobuyuki Ono, Tatsuya Kai, Yasutaka Kimoto, Miki Nakano, Yasushi Inoue, Naoyasu Ueda, Tomoya Miyamura, Kyoko Otsuka, Yuya Shinkawa, Yoshifumi Tada, Mitsuteru Akahoshi, Hiroaki Niiro
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag523
URL
https://doi.org/10.1093/rheumatology/keag523
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.